Diamyd Medical secures FDA fast track status for type 1 diabetes treatment
Diamyd Medical has announced the receipt of fast track designation from the US Food and Drug Administration (FDA) for type 1 diabetes treatment, Diamyd.
Diamyd Medical has announced the receipt of fast track designation from the US Food and Drug Administration (FDA) for type 1 diabetes treatment, Diamyd.
Aardvark Therapeutics has secured $85m in an oversubscribed Series C financing round, with Decheng Capital spearheading the investment, to complete studies of ARD-101.
Rhythm Pharmaceuticals and Genpharm Services FZ have announced a partnership to commercialise IMCIVREE (setmelanotide) for patients in Gulf Cooperation Council (GCC) countries.
Rhythm Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for IMCIVREE (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).